The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $930,825 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, California. The purpose of this 1-year grant is to develop and optimize a high-throughput screening assay to identify small molecule compounds that can overcome the inhibition of remyelination caused by the presence of fibrinogen in the brain, which is a key pathological feature of multiple sclerosis (MS). The screening will evaluate a library of 28,690 compounds for their ability to promote the differentiation of oligodendrocyte progenitor cells into mature myelin-producing oligodendrocytes in the presence of fibrinogen. Promising "hit" compounds from the primary screen will then undergo further testing in secondary assays to assess their safety profile and mechanism of action in regulating bone morphogenetic protein receptor activation, cholesterol synthesis, and anti-inflammatory effects. The goal is to advance potential therapeutic candidates for future clinical development to treat MS by overcoming the extrinsic inhibition of remyelination.
Generated 2/25/25, 4:36 AM